إجمالي مرات مشاهدة الصفحة

الأحد، 6 فبراير 2011

Two dead as Tunisian police fires on protesters


(Reuters) - At least two people were killed and 17 others wounded in northern Tunisia on Saturday when police opened fire to quell a protest after a senior police officer slapped a woman in the face, official and media sources said.
The head of police in the city of El Kef was arrested after the shooting, an Interior Ministry source said.
Four policemen had been arrested earlier on Saturday on suspicion of links to the death on Friday of two civilians while in police custody in Sidi Bouzid, the epicenter of a popular revolt that ousted last month President Zine al-Abidine Ben Ali and reverberated across the Arab world.
Public confidence in the police has been at a low since the revolt, with many Tunisians blaming police officers for killing protesters and associating them with the ousted president.
A rally by hundreds of protesters in front of the police station in El Kef, north of the capital Tunis, degenerated when they tried to occupy its premises, the ministry source said.
"About 1,000 people gathered in a protest in front of El Kef's police station to demand the dismissal of the head of the police in the city for power abuse while exercising his duties," the source told Reuters.
Witnesses told state-run television that the protest started after the police chief slapped a woman in the face.
Protesters later pelted the police station with stones and threw fire bombs at the force guarding the building. Footage on state-run television showed a police van on fire.
"The police fired to prevent the protesters from breaking into the station," the ministry source said.
Four policemen were earlier arrested in Sidi Bouzid on suspicion they were linked to the death on Friday of two civilians after a police station they were locked in caught fire, a ministry spokesman said.
A young unemployed man from Sidi Bouzid, Mohamed Bouazizi, set himself on fire in December to protest at his mistreatment by a police force member. He later died. His act started the anti-government protests which toppled Ben Ali.

Hackers Gained Access to Nasdaq Systems, but Not Trades


Computer hackers have breached the systems of the company that runs the Nasdaq stock exchange in New York but did not penetrate the part of the system that handles trades, Nasdaq said Saturday.

The exchange’s operating company, Nasdaq OMX, said in a statement that it had discovered suspicious files on its United States servers, and that it immediately began conducting an investigation in conjunction with outside firms and federal law enforcement agencies.
Government and law enforcement officials with knowledge of the investigation said it was being handled by the F.B.I.’s cybercrimes branch along with the Justice Department. These officials also said it appeared that the trading platform was not breached.
An attack on banks and other pillars the financial system has long been a top fear of government officials because of the potential for harm to the economy.
Nasdaq is one of the country’s largest stock exchanges, and many of the nation’s most important companies use it to list their shares for trading. If there were evidence that hackers could breach the inner trading systems, it could cause jitters among the companies listed on the exchange and the traders and investors who buy and sell millions of shares each day.
But Nasdaq and market experts said there was an important distinction between the parts of the system that are connected to the Web, and thus more vulnerable, and the architecture for the trading platform, which Nasdaq says operates independently.
The company said it had determined that a Web-based application on its servers called Directors Desk, on which corporations can store and share information, might have been affected. Nasdaq said the suspicious files “were immediately removed and at this point there is no evidence that any Directors Desk customer information was accessed or acquired by hackers.”
“At no point was any of Nasdaq OMX’s operated or serviced trading platforms compromised,” the company said.
The company’s Web site says Directors Desk has 5,000 users.
A spokesman for the company said it discovered the suspicious files late last year.
The fact that investigators discovered suspicious files suggests that the breach involved the installation of malicious software, or malware, said Ed Stroz, a former FBI agent who is co-president of Stroz Friedberg, a firm that investigates cyberattacks.
In attacks on companies, Mr. Stroz said, hackers often plant malware that acts as a back door, which allows them to deliver other malicious programs to do other tasks, which could include copying sensitive data and delivering it to the intruder.
Malware could have been installed any number of ways, including with an attack through the Web interface of Directors Desk or by infiltrating an executive’s computer by tricking him into opening an attachment or clicking on a link to a malicious Web page in an e-mail.
Nasdaq now handles about 19 percent of stock trading in the United States, compared with 27 percent by the larger New York Stock Exchange and its electronic trading arm.
In a statement, the New York Stock Exchange said: “We take any potential threat seriously and we continue working at the highest levels of security and integrity.” The N.Y.S.E. would not say whether there had been any attempts to breach its systems or whether it had been contacted by federal investigators.
News of the breach was originally reported in The Wall Street Journal.
Nasdaq said it had refrained from notifying its customers of the breach at the request of the Justice Department, “in order to facilitate the continuing investigation,” but that when the Journal article appeared it consulted with authorities and decided to send out notice.
The Journal article said the investigation showed some evidence pointing toward Russia. One government official said investigators were specifically looking into that possibility, although the official said, “I don’t know what the basis for the belief is.”
The stock exchanges and the trading that takes place on them have become increasingly computerized, potentially making them more vulnerable to manipulation or attack. Like Nasdaq, the N.Y.S.E. has also adopted more electronic trading. And in the last five years or so, other electronic exchanges like Direct Edge and BATS Exchange have arisen, intent on prying trading away from the two bigger markets. Direct Edge and BATS each handle about 10 percent of the market.
A spokesman for the BATS Exchange said it had never had any hacking issue of this kind.
A spokesman for Direct Edge, Rafi Reguer, said it was continually monitoring its systems but was not aware of any serious attempt to penetrate its computers.
Reporting was contributed by Charlie Savage, Joseph Goldstein, Riva Richmond and William K. Rashbaum
.

Cancer on the Rise in Developing Countries: Report


FRIDAY, Feb. 4 (HealthDay News) -- To mark World Cancer Day, the American Cancer Society issued a new report Friday warning that changing lifestyles linked to economic growth in developing countries are driving up the global incidence of several cancers.
In fact, the majority of the world's new cancer cases and deaths (7.1 million and 4.8 million, respectively) are now occurring in economically developing countries, the authors of the report noted. And this, they say, reflects the growing adoption of unhealthy behaviors -- such as smoking, sedentary lifestyles and poor diets -- that typically accompany economic development.
The report, "Global Cancer Facts & Figures," highlights lung, breast and colorectal cancers as being particularly vulnerable to this dynamic.
Along those lines, about one-third of all cancer deaths that occurred worldwide in 2008 (equal to roughly 7,300 deaths per day) might have been avoided by focusing on preventable risk factors such as smoking, drinking, infection patterns and dietary habits, American Cancer Society chief medical officer Dr. Otis W. Brawley suggested in an editorial accompanying the report.
"The worldwide application of existing cancer control knowledge according to the capacity and economic development of countries or regions could lead to the prevention of even more cancer deaths in the next two to three decades," he stated in a news release from the society.
"In order to achieve this, however, national and international public health agencies, governments, donors, and the private sectors must play major roles in the development and implementation of national or regional cancer control programs worldwide," he added.
The full American Cancer Society analysis is slated to be published, along with Brawley's editorial, in the Feb. 4 edition of CA: A Cancer Journal for Clinicians.
The authors of the report noted that as stark as global disease figures already were in 2008 (12.7 million new cancer cases and 7.6 million cancer deaths), those numbers are expected to almost double by 2030 as the world's population both grows and ages.
In economically developed nations, as of 2008, prostate, lung and colorectal cancers are the most prevalent among men, while breast, colorectal and lung cancers are the most common among women.
By contrast, in developing countries, the biggest risk for men appears to be lung, stomach and liver cancers, with breast, cervical and lung cancers the primary cancer threats for women.
The authors also noted that while just 10 percent of all cancers in the economically developed world are a function of infection, that figure rises to one-quarter of all cancers in the economically developing world.

Sanofi, Genzyme Boards Said Near to Approving Takeover at About $74-Share


Sanofi-Aventis SA and Genzyme Corp. are likely to approve a takeover of the U.S. biotechnology company today and are discussing a price of about $74 a share plus potential additional payments tied to the performance of a Genzyme drug, said four people with knowledge of the plan.
A so-called contingent value right, a tradeable contract tied to Genzyme’s experimental multiple sclerosis drug Lemtrada, may be valued at about $3 when it begins trading and have a higher nominal value, said three people, who declined to be identified because the process is confidential.
The companies’ boards are scheduled to vote on the deal today and may make an announcement on Feb. 7, said the people. Sanofi is still working on its review of Genzyme’s business, an agreement hasn’t been reached, and terms could still change, the people said.
“As we have previously said, we’ve signed a confidentiality agreement with Genzyme and are continuing to review non-public information,” Jean-Marc Podvin, a spokesman for Paris-based Sanofi, said in a telephone interview. “Those talks continue to progress. We have no further comment.”
Bo Piela, a spokesman for Cambridge, Massachusetts-based Genzyme, declined to comment.
Excluding the CVR, a deal may value Genzyme at about $19.2 billion. Genzyme rose 14 cents, or 0.2 percent, to $73.40 in Nasdaq Stock Market trading on Feb. 4. Sanofi gained 30 cents, or 0.6 percent, to 50.30 euros in Paris.
‘Good Deal’
Acquiring Genzyme, the world’s largest maker of medicines for rare genetic disorders, would help Sanofi Chief Executive Officer Chris Viehbacher offset revenue losses as some of Sanofi’s biggest-selling products face competition from generic versions. Sanofi would gain treatments for Fabry, Gaucher and Pompe diseases.
“Genzyme is a good deal for Sanofi,” Frederic Aubel, a sales trader at Global Equities in Paris, said in a telephone interview. “It seems as if they will be paying a good price, and the CVR will protect them from potential bad surprises.”
Genzyme has projected peak annual sales of as much as $3.5 billion for Lemtrada, known as Campath when used for blood cancer. Sanofi said in October that analysts’ estimates of about $700 million were a valuation “probably closer to the reality of the product.” Lemtrada is in the final stages of testing and Genzyme expects data from those trials this year.
Merck-Schering
The acquisition would be the biggest industry takeover since Merck & Co. bought rival Schering-Plough Corp. for about $47 billion in November 2009, according to Bloomberg data.
Viehbacher began pursuing Genzyme last year when the U.S. company was focused on fixing manufacturing snags that cut into sales of its biggest products after a virus contamination at a Boston-area factory. Shire Plc took market share from Genzyme, and Genzyme’s stock sank as much as 43 percent from a 2008 high, causing unrest among shareholders.
The Sanofi chief told Genzyme CEO Henri Termeer, 64, of his interest in acquiring Genzyme in a May 23 conversation, according to a filing with the Securities and Exchange Commission last year. Sanofi announced a $69-a-share, $18.5 billion cash bid on Aug. 29 after Termeer refused to negotiate. The French company went directly to shareholders with a hostile tender offer on Oct. 4 after Genzyme continued to spurn the offer as too low.
Starting Talks
Sanofi said the offer allowed Genzyme shareholders to cash out after “quite a lengthy period” when the stock underperformed. Genzyme fired back that the offer was “inadequate and opportunistic.” The company already had been targeted by activist investors Ralph Whitworth of Relational Investors LLC and Carl C. Icahn, who gained four of 13 board seats last year in compromises brokered with Genzyme to avoid a proxy battle.
The companies later began negotiations over the proposal and said Jan. 31 that they had started due diligence. Genzyme said it would provide data such as profit margins and customer lists, which Sanofi agreed not to divulge. The $69-a-share tender offer is set to expire Feb. 15.
Genzyme’s top-selling medicine, which garnered $722 million in sales in 2010, is Cerezyme, a mass-produced version of a human enzyme missing in patients with the inherited illness Gaucher disease. The medicine had sales of more than $1 billion in 2007 and 2008 before shortages caused by the plant contamination.
Genzyme’s Drugs
Fabrazyme, used to treat the genetic illness Fabry disease, and Myozyme and Lumizyme for Pompe disease, similarly provide patients with enzymes their bodies fail to make or produce adequately on their own.
Unlike the pills produced by traditional drug companies, Genzyme’s medicines are made using biological processes and can’t be readily copied by generic-drug makers. Genzyme garners premium prices from insurers and government payers because the therapies provide life-saving benefits.
Genzyme, founded in 1981, has about 10,000 employees and 12 manufacturing facilities worldwide, according to the company’s website. Its products are available in almost 100 countries.
Genzyme is being advised by Credit Suisse Group AG and Goldman Sachs Group Inc. Sanofi is advised by Evercore Partners Inc., JPMorgan Chase & Co. and Morgan Stanley.

Charlie Sheen's Porn Star -- Spreading for GQ

Nothing says "high society" like a cocaine-fueled bender with Charlie Sheen ... so maybe that's why hisporn star party pal just scored a fancy photo shoot with GQ Magazine.

0203_kacey_jordan_gq_tmz_ex

TMZ has learned Kacey Jordan -- the chick who got paid $30k to kick it with Sheen during his bender -- struck a pose for a GQ shoot in Beverly Hills yesterday.

Must have been a whole new experience for Kacey -- she's not used to posing with her clothes on. 

Inception and Social Network win Writers Guild awards





Sci-fi thriller Inception and Facebook movie The Social Network have won the main prizes at the Writers Guild of America (WGA) awards.
Inception, which stars Leonardo DiCaprio, won best original screenplay, while The Social Network was named best adapted screenplay.
The King's Speech, which is nominated for 12 Oscars, was ineligible for the awards and did not make the shortlist.
Winners were announced at simultaneous ceremonies in New York and Los Angeles.
British-born film-maker Christopher Nolan, who wrote, produced and directed Inception, called the award an "incredible honour".
He said the prize would have been more significant if "certain other screenplays" had been nominated, without naming The King's Speech.
Nolan added that he had been "heartbroken" when the script for Memento had fallen outside WGA guidelines nine years ago.
Social Network writer Aaron Sorkin said: "I wrote a good screenplay, but [director] David Fincher made a great movie."
The writers of Mad Men were honoured for best television drama, with Boardwalk Empire collecting the award for outstanding new TV drama.
British screenwriter Peter Morgan, whose previous credits include The Queen and Frost/Nixon, was awarded for his work on small screen drama The Special Relationship.
The WGAs are seen as a good indicator of which films will win writing plaudits at the Oscars, because many of its members also belong to the Academy.

Sanders, Faulk among 7 joining Hall of Fame


DALLAS -- Two of the most electrifying players of their generation are going to the Pro Football Hall of Fame, along with the man who chronicled their exploits.
First-year eligibles Deion Sanders and Marshall Faulk were voted to the Hall of Fame on Saturday, along with NFL Films founder Ed Sabol.
Joining them in the seven-man class selected in a 71/2-hour meeting were defensive end Richard Dent, tight end Shannon Sharpe and seniors committee candidates Chris Hanburger and Les Richter, linebacker stars of previous eras.

The most spirited debate in the discussion concerned Sabol, who turned a small film company into a legacy-building empire.
NFL Films, with its extreme slow-motion shots, dramatic music and the booming baritone of announcer John Facenda, shaped the way many football fans view the game.
His supporters insisted the 94-year-old Sabol set the stage for the dramatic growth of the NFL's popularity, pushing it far beyond baseball and college sports.
Sanders and Faulk were considered favorites and proved to be, pushing through the lengthiest meeting in the committee's history.
While not all favored his cover-first style, Sanders defined the cover corner position at a time when he hopscotched between the NFL and major league baseball and became a cross-cultural icon.
Faulk's recognition stemmed from his exploits as the backbone of "The Greatest Show on Turf," the St. Louis offenses from the 1990s. Faulk is ninth on the league's all-time rushing list and 16th all-time in receptions, showing the kind of versatility that made those Rams teams so dangerous.
Dent pushed through in his ninth year of eligibility, finally being recognized for his defining pass rush in an era that was only beginning to quantify it. His 137.5 sacks rank sixth all-time, but his tough defense against the run made him one of the stalwarts of one of the league's great defenses. He was named MVP of Super Bowl XX after forcing two fumbles and registering 1.5 sacks in the Bears' win.
Sharpe changed the way the tight end's role was viewed. Though he was an able blocker, he left the game as the leader in receptions (815), yards (10,060) and touchdowns (62) by a tight end.
Hanburger and Richter were chosen by the veterans committee, which brings forgotten stars back for discussion. Hanburger played at North Carolina before his stellar career with the Washington Redskins, while Richter was one of the league's original enforcers for the Los Angeles Rams in the 1950s and early '60s.
In addition to the seniors committee candidates, 15 players were finalists.
Wide receivers Cris Carter and Tim Brown, defensive ends Chris Doleman and Charles Haley, and running back Jerome Bettis were eliminated in the first cut to 10.
When the list was reduced to the final five candidates, center Dermontti Dawson, defensive tackle Cortez Kennedy, running back Curtis Martin, wide receiver Andre Reed and offensive tackle Willie Roaf fell by the wayside.